Didier Jean-Claude Berthelot

USPTO Granted Patents = 23 (Patent Applications = 2)

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 11 (Patent Applications = 11)

Average Co-Inventor Count = 7.6

ph-index = 3

Forward Citations = 39(Granted Patents)

Location History:

Antwerpen, BE (2012 - 2014)
Antwerp, BE (2013 - 2015)
Edegem, BE (2015)
Turnhoutseweg, BE (2015)
Issy-les Moulineaux, FR (2021)
La Neuville Chang d'Oisel, FR (2021)
La Neuville Chant d'Oisel, FR (2018 - 2024)

Company Filing History:

15 out of 2,078

Janssen Pharmaceutica Nv

patents

8 out of 159

Janssen Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404260 - Pyridine rings containing derivatives as MALT1 inhibitors (2025-09-02),

2. 12077521 - Pyrazole derivatives as MALT1 inhibitors (2024-09-03),

3. 11267804 - (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity (2022-03-08),

4. 11130751 - Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors (2021-09-28),

5. 10954214 - Pyrazole derivatives as MALT1 inhibitors (2021-03-23),

6. 10898504 - Substituted nucleoside analogues for use as PRMT5 inhibitors (2021-01-26),

7. 10894793 - Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors (2021-01-19),

8. 10888550 - Pyrazole derivatives as MALT1 inhibitors (2021-01-12),

9. 10526316 - Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors (2020-01-07),

10. 10202387 - Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors (2019-02-12),

11. 10087187 - Imidazopyridazine derivatives as PI3KB inhibitors (2018-10-02),

12. 10017509 - Macrocylic pyrimidine derivatives (2018-07-10),

13. 9145399 - Substituted bicyclic triazole derivatives as gamma secretase modulators (2015-09-29),

14. 9115143 - Substituted indole derivatives as gamma secretase modulators (2015-08-25),

15. 9079886 - Substituted triazole derivatives as gamma secretase modulators (2015-07-14),

Title: Didier Jean-Claude Berthelot: Innovator in Pharmaceutical Patents

Introduction

Didier Jean-Claude Berthelot is a prominent inventor based in La Neuville Chant d'Oisel, France. With a total of 22 patents to his name, Berthelot has made significant contributions to the field of pharmaceuticals, particularly in the development of novel therapeutic compounds. His work focuses on creating innovative solutions for various medical conditions through the modulation of specific biological pathways.

Latest Patents

Berthelot's latest patents reflect his dedication to advancing medical treatments. One notable patent involves pyrazole derivatives as MALT1 inhibitors. This invention discloses compounds, compositions, and methods for treating diseases that are influenced by the modulation of MALT1. The compounds are represented by a specific formula, providing a blueprint for future research and application.

Another significant patent pertains to a compound designated as (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide, aimed at inhibiting phosphoinositide-3-kinase activity. This invention introduces substituted quinoxaline and pyridopyrazine derivatives, which are useful as inhibitors for pI3Kβ. It also includes pharmaceutical formulations containing these compounds, highlighting their potential as medicaments.

Career Highlights

Berthelot has established a commendable career in the pharmaceutical industry, working for notable companies such as Janssen Pharmaceutica and Janssen Pharmaceuticals. His expertise in drug development and patenting has allowed him to lead innovative projects that address significant medical challenges.

Collaborations

Throughout his career, Berthelot has collaborated with esteemed colleagues, including Lieven Meerpoel and Henricus Jacobus Maria Gijsen. These collaborations have enriched his research, leading to the successful development of new therapeutic agents and enhancing the overall impact of his work on the pharmaceutical landscape.

Conclusion

Didier Jean-Claude Berthelot stands out as a key figure in the realm of pharmaceutical innovations. With a portfolio of 22 patents and a commitment to advancing medical therapies, he continues to contribute to the scientific community. His inventions not only provide insights into the modulation of crucial biological pathways but also hold the promise of improving patient outcomes in various diseases.

This text is generated by artificial intelligence and may not be accurate.